Pharmacological properties of 3-(p-chlorobenzyl) quinolizidine tartarate (QB-1), a new oxytocic.
D000818:Animals; D001001:Anura; D001522:Behavior, Animal / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D002490:Central Nervous System / Q000187:drug effects; D004285:Dogs; D004562:Electrocardiography; D004569:Electroencephalography; D005260:Female; D005769:Gastrointestinal Motility / Q000187:drug effects; D006321:Heart / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D007421:Intestine, Small / Q000187:drug effects; D008297:Male; D051379:Mice; D009119:Muscle Contraction / Q000187:drug effects; D010120:Oxytocics; D010424:Pentobarbital / Q000494:pharmacology; D011807:Quinolizines / Q000494:pharmacology* / Q000633:toxicity; D011817:Rabbits; D051381:Rats; D012039:Regional Blood Flow / Q000187:drug effects; D012119:Respiration / Q000187:drug effects; D013034:Sparteine / Q000494:pharmacology; D014599:Uterus / Q000187:drug effects
D010120:Oxytocics; D011807:Quinolizines; D013034:Sparteine; D010424:Pentobarbital